TY - JOUR
T1 - Comparison of DES vs DES + chlorambucil in women with first recurrence of breast cancer
AU - Holzer, Donald
AU - Harvey, Harold
AU - Lipton, Allan
PY - 1979
Y1 - 1979
N2 - Thirty‐four women with first recurrence of breast cancer were randomized into two groups, and received either Diethystilbesterol (DES) 5 mg orally (PO) t.i.d. alone, or in combination with Chlorambucil (CB) 0.1–0.2 mg/kg/day PO. All patients randomized were greater than 5 years postmenopausal at the time of the study and had no prior chemical or hormonal therapy. Estrogen receptors were not available. There was no significant difference between Groups A and B with respect to frequency of objective response or mean duration of that response, with the values for Group A being 46.2% and 4.8 months, respectively, and for Group B, 46.7% and 4.8 months (P > 0.05). The most common toxicities noted for both groups were nausea and vomiting, edema, weakness, and thrombophlebitis. The risk of major toxicity necessitating withdrawal from the study was greater in Group B due to the added danger of thrombocytopenia/pancytopenia. The addition of CB to DES does not appear to offer any significant advantage over DES alone in women with first recurrence of breast cancer.
AB - Thirty‐four women with first recurrence of breast cancer were randomized into two groups, and received either Diethystilbesterol (DES) 5 mg orally (PO) t.i.d. alone, or in combination with Chlorambucil (CB) 0.1–0.2 mg/kg/day PO. All patients randomized were greater than 5 years postmenopausal at the time of the study and had no prior chemical or hormonal therapy. Estrogen receptors were not available. There was no significant difference between Groups A and B with respect to frequency of objective response or mean duration of that response, with the values for Group A being 46.2% and 4.8 months, respectively, and for Group B, 46.7% and 4.8 months (P > 0.05). The most common toxicities noted for both groups were nausea and vomiting, edema, weakness, and thrombophlebitis. The risk of major toxicity necessitating withdrawal from the study was greater in Group B due to the added danger of thrombocytopenia/pancytopenia. The addition of CB to DES does not appear to offer any significant advantage over DES alone in women with first recurrence of breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0018422231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018422231&partnerID=8YFLogxK
U2 - 10.1002/jso.2930120102
DO - 10.1002/jso.2930120102
M3 - Article
C2 - 480949
AN - SCOPUS:0018422231
VL - 12
SP - 1
EP - 9
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 1
ER -